TP53 and cancer: It has been known for some time that DNA-damaging cancer drugs have the ability to increase innate immune receptor expression on tumour cells; so the upregulation of CD95 in these cell lines was no surprise given that they express functional p53, which is thought necessary for activating the CD95 gene upon chemotherapy-induced DNA damage23.